GlassScriptPhysician profile
Thomas Gerard Ferry
NPI 1194726406
$27,623.47
in general payments reported to CMS, 2019-2025
29 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,967 · 2020: $9,785 · 2021: $1,690 · 2022: $1,637 · 2023: $1,958 · 2024: $1,866 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $18,187.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,894.46 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,197.29 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols Shared Services North America, INC. | $764.12 | 2021-2025 | Prolastin-C Liquid |
| Grifols USA, LLC | $702.32 | 2019-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $370.06 | 2020-2024 | Acthar |
| Genzyme Corporation | $328.89 | 2021-2024 | |
| Mylan Specialty L.P. | $325.44 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.46 | 2019-2023 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $256.26 | 2020-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $248.38 | 2020-2024 | Glassia |
| Philips North America LLC | $164.58 | 2019-2024 | (Ak6) Vest Therapy |
| Insmed, INC. | $154.12 | 2024-2025 | Arikayce |
| Boston Scientific Corporation | $120.00 | 2021 | |
| United Therapeutics Corporation | $116.62 | 2024 | Tyvaso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.06 | 2022-2024 | |
| Amgen INC. | $70.22 | 2019-2024 | Tezspire |
| Electromed, INC. | $61.64 | 2022-2024 | Smartvest |
| Advanced Respiratory, INC | $54.54 | 2021 | |
| Mallinckrodt Enterprises LLC | $38.44 | 2019 | |
| Shire North American Group INC | $36.55 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.60 | 2024 | Uptravi, Opsumit |
| Itf Therapeutics LLC | $24.60 | 2025 | |
| Octapharma USA, INC. | $18.84 | 2024 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $17.65 | 2023 | |
| Merck Sharp & Dohme LLC | $16.50 | 2023 | |
| Vifor Pharma, INC. | $14.79 | 2024 | Zemaira |
| Amarin Pharma, INC. | $14.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ferry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.